(TGTX) TG Therapeutics - Overview
Stock: Briumvi, Ublituximab, Tg-1701, Tg-1801
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 60.7% |
| Relative Tail Risk | -15.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.13 |
| Alpha | -22.66 |
| Character TTM | |
|---|---|
| Beta | 0.482 |
| Beta Downside | 0.254 |
| Drawdowns 3y | |
|---|---|
| Max DD | 80.91% |
| CAGR/Max DD | 0.22 |
Description: TGTX TG Therapeutics January 09, 2026
TG Therapeutics, Inc. (NASDAQ:TGTX) is a commercial-stage biopharmaceutical firm that develops and markets novel B-cell-targeted therapies, primarily for multiple sclerosis (MS) and other B-cell-mediated diseases. Its flagship product, BRIUMVI (ublituximab), is an anti-CD20 monoclonal antibody approved for adult patients with relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. The pipeline includes a next-generation IV formulation of ublituximab, an oral BTK inhibitor (TG-1701), and a bispecific CD47/CD19 antibody (TG-1801), supported by multiple licensing and collaboration agreements with partners such as LFB, GTC, Jiangsu Hengrui, and Checkpoint Therapeutics.
Key recent metrics: TG Therapeutics reported Q2-2024 revenue of approximately $45 million, driven largely by BRIUMVI sales, while its net loss widened to $120 million as it ramped up R&D spending on the BTK and bispecific programs. The company’s cash runway is estimated at 18 months, assuming current burn rates and no new financing. Sector-wide, the global MS therapeutics market is projected to grow at a CAGR of ~5% through 2029, and BTK inhibitors are gaining traction as a potential oral alternative to infused anti-CD20 antibodies, which could reshape competitive dynamics with incumbents like Roche’s Ocrevus.
For a deeper quantitative dive into TG Therapeutics’ valuation metrics, you may find the ValueRay platform’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 447.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.07 > 0.02 and ΔFCF/TA -2.06 > 1.0 |
| NWC/Revenue: 83.28% < 20% (prev 169.6%; Δ -86.27% < -1%) |
| CFO/TA -0.07 > 3% & CFO -70.1m > Net Income 447.5m |
| Net Debt (179.6m) to EBITDA (115.2m): 1.56 < 3 |
| Current Ratio: 3.82 > 1.5 & < 3 |
| Outstanding Shares: last quarter (161.0m) vs 12m ago 0.18% < -2% |
| Gross Margin: 85.33% > 18% (prev 0.88%; Δ 8445 % > 0.5%) |
| Asset Turnover: 66.03% > 50% (prev 45.18%; Δ 20.85% > 0%) |
| Interest Coverage Ratio: 4.22 > 6 (EBITDA TTM 115.2m / Interest Expense TTM 27.3m) |
Altman Z'' -2.50
| A: 0.43 (Total Current Assets 599.8m - Total Current Liabilities 156.8m) / Total Assets 1.03b |
| B: -1.08 (Retained Earnings -1.11b / Total Assets 1.03b) |
| C: 0.14 (EBIT TTM 115.0m / Avg Total Assets 805.5m) |
| D: -2.64 (Book Value of Equity -1.10b / Total Liabilities 417.8m) |
| Altman-Z'' Score: -2.50 = D |
Beneish M 1.00
| DSRI: 1.14 (Receivables 265.4m/115.7m, Revenue 531.9m/264.8m) |
| GMI: 1.03 (GM 85.33% / 88.25%) |
| AQI: 52.80 (AQ_t 0.41 / AQ_t-1 0.01) |
| SGI: 2.01 (Revenue 531.9m / 264.8m) |
| TATA: 0.50 (NI 447.5m - CFO -70.1m) / TA 1.03b) |
| Beneish M-Score: 29.08 (Cap -4..+1) = D |
What is the price of TGTX shares?
Over the past week, the price has changed by -1.94%, over one month by -1.87%, over three months by -13.23% and over the past year by -13.85%.
Is TGTX a buy, sell or hold?
- StrongBuy: 5
- Buy: 1
- Hold: 0
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the TGTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 44.9 | 55.4% |
| Analysts Target Price | 44.9 | 55.4% |
| ValueRay Target Price | 27.1 | -6.1% |
TGTX Fundamental Data Overview February 03, 2026
P/E Forward = 23.4192
P/S = 8.7842
P/B = 7.8436
Revenue TTM = 531.9m USD
EBIT TTM = 115.0m USD
EBITDA TTM = 115.2m USD
Long Term Debt = 245.3m USD (from longTermDebt, last quarter)
Short Term Debt = 1.89m USD (from shortTermDebt, last quarter)
Debt = 253.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 179.6m USD (from netDebt column, last quarter)
Enterprise Value = 4.79b USD (4.67b + Debt 253.7m - CCE 131.6m)
Interest Coverage Ratio = 4.22 (Ebit TTM 115.0m / Interest Expense TTM 27.3m)
EV/FCF = -68.26x (Enterprise Value 4.79b / FCF TTM -70.2m)
FCF Yield = -1.47% (FCF TTM -70.2m / Enterprise Value 4.79b)
FCF Margin = -13.21% (FCF TTM -70.2m / Revenue TTM 531.9m)
Net Margin = 84.13% (Net Income TTM 447.5m / Revenue TTM 531.9m)
Gross Margin = 85.33% ((Revenue TTM 531.9m - Cost of Revenue TTM 78.0m) / Revenue TTM)
Gross Margin QoQ = 82.59% (prev 86.58%)
Tobins Q-Ratio = 4.68 (Enterprise Value 4.79b / Total Assets 1.03b)
Interest Expense / Debt = 2.65% (Interest Expense 6.72m / Debt 253.7m)
Taxrate = 8.64% (2.21m / 25.6m)
NOPAT = 105.1m (EBIT 115.0m * (1 - 8.64%))
Current Ratio = 3.82 (Total Current Assets 599.8m / Total Current Liabilities 156.8m)
Debt / Equity = 0.42 (Debt 253.7m / totalStockholderEquity, last quarter 607.2m)
Debt / EBITDA = 1.56 (Net Debt 179.6m / EBITDA 115.2m)
Debt / FCF = -2.56 (negative FCF - burning cash) (Net Debt 179.6m / FCF TTM -70.2m)
Total Stockholder Equity = 335.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 55.55% (Net Income 447.5m / Total Assets 1.03b)
RoE = 133.2% (Net Income TTM 447.5m / Total Stockholder Equity 335.8m)
RoCE = 19.79% (EBIT 115.0m / Capital Employed (Equity 335.8m + L.T.Debt 245.3m))
RoIC = 20.22% (NOPAT 105.1m / Invested Capital 519.5m)
WACC = 7.42% (E(4.67b)/V(4.93b) * Re(7.69%) + D(253.7m)/V(4.93b) * Rd(2.65%) * (1-Tc(0.09)))
Discount Rate = 7.69% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 6.07%
Fair Price DCF = unknown (Cash Flow -70.2m)
EPS Correlation: 60.03 | EPS CAGR: 135.2% | SUE: -0.42 | # QB: 0
Revenue Correlation: 80.37 | Revenue CAGR: 210.1% | SUE: 0.23 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.33 | Chg30d=+0.003 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=1.78 | Chg30d=-0.168 | Revisions Net=-1 | Growth EPS=-40.8% | Growth Revenue=+45.3%